Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPYD | Q12882 | 5/20 | 0.59 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HBB | P68871 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TYMP | P19971 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6374582 | 1.00 | DPYD (0.59) | DPYDATAD2MAPTGAAALDH1A1 | |
| SCHEMBL65892 | 0.79 | DPYD (0.62) | DPYDATAD2MAPTGAAALDH1A1 | |
| SCHEMBL8776005 | 0.79 | DPYD (0.59) | DPYDATAD2MAPTGAAALDH1A1 | |
| SCHEMBL12903446 | 0.79 | DPYD (0.59) | DPYDATAD2MAPTGAAALDH1A1 | |
| SCHEMBL190003 | 0.79 | DPYD (0.62) | DPYDATAD2MAPTGAAALDH1A1 | |
| SCHEMBL190377 | 0.79 | DPYD (0.59) | DPYDATAD2MAPTGAAALDH1A1 | |
| SCHEMBL190378 | 0.79 | DPYD (0.59) | DPYDATAD2MAPTGAAALDH1A1 | |
| SCHEMBL933037 | 0.79 | DPYD (0.59) | DPYDATAD2MAPTGAAALDH1A1 | |
| SCHEMBL15798473 | 0.79 | DPYD (0.62) | DPYDATAD2MAPTGAAALDH1A1 | |
| SCHEMBL7606812 | 0.79 | DPYD (0.53) | DPYDATAD2MAPTGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2895607-B1 | DOUBLE-STRANDED OLIGONUCLEOTIDE MOLECULES TO DDIT4 AND METHODS OF USE THEREOF | QUARK PHARMACEUTICALS INC (US) | 2021-05-05 | — | — | EP | claimed |
| US-9611474-B2 | Double-stranded oligonucleotide molecules to DDIT4 and methods of use thereof | QUARK PHARMACEUTICALS, INC. (US) | 2017-04-04 | — | — | US | claimed |
| US-20150267194-A1 | DOUBLE-STRANDED OLIGONUCLEOTIDE MOLECULES TO DDIT4 AND METHODS OF USE THEREOF | Quark Pharmaceutical, Inc. (US) | 2015-09-24 | — | — | US | claimed |
| EP-2895607-A2 | DOUBLE-STRANDED OLIGONUCLEOTIDE MOLECULES TO DDIT4 AND METHODS OF USE THEREOF | Quark Pharmaceuticals, Inc. (US) | 2015-07-22 | — | — | EP | claimed |
| WO-2013020097-A9 | DOUBLE-STRANDED OLIGONUCLEOTIDE COMPOUNDS FOR TREATING HEARING AND BALANCE DISORDERS | QUARK PHARMACEUTICALS, INC. (US) | 2014-06-12 | — | — | WO | claimed |
| EP-2739637-A1 | DOUBLE-STRANDED OLIGONUCLEOTIDE COMPOUNDS FOR TREATING HEARING AND BALANCE DISORDERS | Quark Pharmaceuticals, Inc. (US) | 2014-06-11 | — | — | EP | claimed |
| WO-2014043289-A2 | DOUBLE-STRANDED OLIGONUCLEOTIDE MOLECULES TO DDIT4 AND METHODS OF USE THEREOF | QUARK PHARMACEUTICALS, INC. (US) | 2014-03-20 | — | — | WO | claimed |
| WO-2013020097-A1 | DOUBLE-STRANDED OLIGONUCLEOTIDE COMPOUNDS FOR TREATING HEARING AND BALANCE DISORDERS | QUARK PHARMACEUTICALS, INC. (US) | 2013-02-07 | — | — | WO | claimed |
| WO-2025082058-A1 | DSRNA THAT INHIBITS EXPRESSION OF LPA GENE AND USE THEREOF | 润佳(上海)医药技术有限公司 | 2025-04-24 | — | — | WO | disclosed |
| WO-2025082057-A1 | INHIBITOR FOR INHIBITING EXPRESSION OF INHIBIN BETA E GENE AND USE THEREOF | 润佳(上海)医药技术有限公司 | 2025-04-24 | — | — | WO | disclosed |
| US-20050090659-A1 | Phospholepid derivatives of nucleosides as antitumaorl medicaments | GANYMED 256 VERMOEGENSVERWALTUNGS GMBH (DE) | 2005-04-28 | — | — | US | disclosed |
| EP-1448579-A1 | PHOSPHOLIPID DERIVATIVES OF NUCLEOSIDES AS ANTITUMORAL MEDICAMENTS | Heidelberg Pharma Holding GmbH (DE) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003044035-A1 | PHOSPHOLIPID DERIVATIVES OF NUCLEOSIDES AS ANTITUMORAL MEDICAMENTS | GANYMED 256 VERMÖGENSVERWALTUNGS GMBH (DE) | 2003-05-30 | — | — | WO | disclosed |
| EP-0135587-B2 | DEFINED SEQUENCE SINGLE STRAND OLIGONUCLEOTIDES INCORPORATING REPORTER GROUPS, PROCESS FOR THE CHEMICAL SYNTHESIS THEREOF, AND NUCLEOSIDES USEFUL IN SUCH SYNTHESIS | SYNGENE INC (US) | 2002-12-18 | — | — | EP | disclosed |
| EP-0097376-B1 | NUCLEOSIDE 5'-ALKYL- OR ALKENYLPHOSPHATE | Yamasa Shoyu Kabushiki Kaisha (JP) | 1986-09-17 | — | — | EP | disclosed |
| EP-0135587-A4 | DEFINED SEQUENCE SINGLE STRAND OLIGONUCLEOTIDES INCORPORATING REPORTER GROUPS, PROCESS FOR THE CHEMICAL SYNTHESIS THEREOF, AND NUCLEOSIDES USEFUL IN SUCH SYNTHESIS. | MOLECULAR BIOSYSTEMS INC (US) | 1986-04-02 | — | — | EP | disclosed |
| EP-0135587-A1 | DEFINED SEQUENCE SINGLE STRAND OLIGONUCLEOTIDES INCORPORATING REPORTER GROUPS, PROCESS FOR THE CHEMICAL SYNTHESIS THEREOF, AND NUCLEOSIDES USEFUL IN SUCH SYNTHESIS. | MOLECULAR BIOSYSTEMS INC (US) | 1985-04-03 | — | — | EP | disclosed |
| WO-1984003285-A1 | DEFINED SEQUENCE SINGLE STRAND OLIGONUCLEOTIDES INCORPORATING REPORTER GROUPS, PROCESS FOR THE CHEMICAL SYNTHESIS THEREOF, AND NUCLEOSIDES USEFUL IN SUCH SYNTHESIS | MOLECULAR BIOSYSTEMS INC (US) | 1984-08-30 | — | — | WO | disclosed |
| EP-0097376-A1 | Nucleoside 5'-alkyl- or alkenylphosphate | Yamasa Shoyu Kabushiki Kaisha (JP) | 1984-01-04 | — | — | EP | disclosed |
| US-4247544-A | C-5 Substituted uracil nucleosides | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1981-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090659-A1 | Phospholepid derivatives of nucleosides as antitumaorl medicaments | PHOSPHO1, TYMP, PNP | DPYD 39/4885ATAD2 2353/4885MAPT 4509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.